Comparison · NCT04399980-a5cb368a
Intervention vs Control: Number of Subjects Alive and Without Respiratory Failure at Day 28
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intervention vs Control: Number of Subjects Alive and Without Respiratory Failure at Day 28. Trial comparisons, record NCT04399980-a5cb368a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04399980-a5cb368a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.952 | 0.773 | 0.992 | wilson | |
| Risk in group 2 | 0.789 | 0.567 | 0.915 | wilson | |
| Risk difference, group 1 minus group 2 | 0.163 | -0.0557 | 0.389 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.21 | 0.938 | 1.55 | log | |
| Odds ratio, group 1 over group 2 | 5.33 | 0.539 | 52.7 | log | |
| Number needed to treat, for one more participant with the outcome on Intervention than on Control | 6.14 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intervention | One-time Mavrilimumab infusion at 6mg/kg via IV | 20 | 21 | OG000 |
| Group 2 | Control | One-time placebo infusion via IV | 15 | 19 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Alive and Without Respiratory Failure at Day 28
- Description
- Number and percentage of subjects that are alive and without respiratory failure at Day 28
- Time frame
- Day 28
- Population
Source ClinicalTrials.gov
Trial
- Title
- Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
- NCT number
- NCT04399980
- Phases
- PHASE2
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Interventions
- Mavrilimumab, Placebos
- Lead sponsor
- The Cleveland Clinic
- Results first posted
- 2021-05-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04399980?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04399980-a5cb368a